Skip to content

Psilocybin research published in 2022

Page 5 of 14: studies 81 to 100 of 277, newest first. Back to the psilocybin overview

Studies

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs

Frontiers in Psychiatry October 3, 2022 Jordi Camarasa, Pol Puigseslloses, Edurne Urquizu et al. 5 citations

The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects. Psychoactive substances have a long history of being used as tools to alter consciousness and as a gateway to approach the unknown and the divinities. These substances were initially obtained from plants...

Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.

International Journal of Drug Policy October 2022 Adam W. Levin, Paul Nagib, Selina Deiparine et al.

Evidence points to an incongruence between international drug policy and expert opinion about safety, abuse potential, and therapeutic potential of specific drugs. However, no prior studies have directly explored psychiatrists' attitudes about the current drug schedule. Therefore, we examined whether American psychiatrists' perceptions of four psychoactive drugs differed from those indicated by...

Prevalence and associations of classic psychedelic-related seizures in a population-based sample.

Drug and Alcohol Dependence October 1, 2022 Otto Simonsson, Simon B. Goldberg, Richard Chambers et al. 16 citations

Previous studies have reported links between classic psychedelic use and seizures, but little remains known about prevalence and potential risk factors of classic psychedelic-related seizures. Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N = 2822), this study examined the prevalence and potential risk factors of classic psychedelic-related...

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.

Transcultural Psychiatry October 1, 2022 Christopher Timmermann, Rosalind Watts, David Dupuis 112 citations

A striking feature of psychedelics is their ability to increase attribution of truth and meaningfulness to specific contents and ideas experienced, which may persist long after psychedelic effects have subsided. We propose that processes underlying conferral of meaning and truth in psychedelic experiences may act as a double-edged sword: while these may drive important therapeutic benefits,...

Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.

Current Psychiatry Reports October 1, 2022 Damien Prouzeau, Ismaël Conejero, Peter L Voyvodic et al. 32 citations

We aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action. Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effects limited to a few hours after dosing. The studies conducted to date...

DOI: 10.1007/s11920-022-01361-0 (opens in new tab) Full text (opens in new tab) 5-ht2a agonists Hallucinogen Mood disorder Narrative review +2

If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.

Journal of Pain October 1, 2022 Robert H. Dworkin, Brian T Anderson, Nick Andrews et al. 22 citations

Psychedelic substances have played important roles in diverse cultures, and ingesting various plant preparations to evoke altered states of consciousness has been described throughout recorded history. Accounts of the subjective effects of psychedelics typically focus on spiritual and mystical-type experiences, including feelings of unity, sacredness, and transcendence. Over the past 2 decades,...

Why Otolaryngologists Should Be Interested in Psychedelic Medicine.

Otolaryngologic clinics of North America October 1, 2022 Benjamin F Asher

As psychedelic medicine is becoming mainstream, physicians need to know something about these medications, their indications, contraindications, and potential for research. This article is a brief overview of the subject with some ideas of how psychedelic medicines can impact the practice of Otolaryngology-Head and Neck Surgery.

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

CNS Drugs October 1, 2022 Niloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi et al. 16 citations

Preliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of select psychedelics (e.g., psilocybin) suggest that their effects are transdiagnostic. In this review, we exploit the Research Domain Criteria (RDoC) transdiagnostic framework, to synthesize extant literature on psilocybin. We aimed to identify RDoC-based effects of...

DOI: 10.1007/s40263-022-00944-y (opens in new tab) Full text (opens in new tab) Psychedelics Mental health research Behavioral neuroscience Psilocybin therapy +1

The Emerging Field of Psychedelic Psychotherapy.

Current Psychiatry Reports October 1, 2022 Gregory S. Barber, Scott T Aaronson 56 citations

Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as...

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)

BMJ Open October 1, 2022 Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Tobias Søgaard Juul et al. 21 citations

Introduction Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly meaningful experiences that may spur a positive change in drinking behaviour when administered in a...

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.

Transcultural Psychiatry October 1, 2022 Gabriella Gobbi, Antonio Inserra, Kyle T. Greenway et al. 9 citations

Psychedelics have been already used by human societies for more than 3000 years, mostly in religious and healing context. The renewed interest in the potential application of psychedelic compounds as novel therapeutics has led to promising preliminary evidence of clinical benefit in some psychiatric disorders. Despite these promising results, the potential for large-scale clinical application...

Microdosing with classical psychedelics: Research trajectories and practical considerations

Transcultural Psychiatry October 1, 2022 Alice Wong, Amir Raz 10 citations

Microdosing—the intermittent ingestion of minute, sub-hallucinogenic amounts of psychedelic substances, repeatedly and over time—has become a widespread, albeit largely understudied, phenomenon. Regulations around using psychedelics at any dose—micro, mini, macro, or mega—pose all sorts of difficulties for those who wish to systematically study the effects of Schedule I drugs, especially in the...

Potential Therapeutic Effects of Psilocybin: A Systematic Review.

Cureus October 1, 2022 Dev B Goel, Sarju Zilate 24 citations

Psilocybin is a plant alkaloid that is derived from precursors of tryptamine and is present in many different types of mushrooms. It has been utilized by indigenous peoples of Central and South America for centuries in a ceremonial setting to promote spiritual experiences. Indigenous societies have long employed psilocybin and other 5-HT 2A agonist classic psychedelics in their rites. They were...

Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review

International Journal of Molecular Sciences September 28, 2022 Dominika Psiuk, Emilia Magdalena Nowak, Natalia Dycha et al. 36 citations

This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment—psilocybin and esketamine. The former is a naturally occurring psychedelic. The latter was invented in the laboratory exactly 60 years ago. Although the substances were controversial in the past, recent studies indicate the potential of those...

Brain dynamics predictive of response to psilocybin for treatment-resistant depression

Research Square September 20, 2022 Jakub Vohryzek, Joana Cabral, Louis-David Lord et al. 10 citations preprint

Abstract Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here we leveraged the differential outcome in responders and non-responders to psilocybin (10mg and 25mg, 7 days apart) therapy for depression - to gain new insights into regions and networks implicated in the restoration of healthy brain dynamics. We used...

Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives – A Computational Study

Letters in Applied NanoBioScience September 17, 2022 3 citations

Medical hallucinogens have been important compounds of research interest in recent years. Computational chemistry methods like Density Functional Theory (DFT) calculations at BP86/Def2-TZVP level are carried out to get more insight into the structural preferences and mechanism of hallucinogens like psilocybin and mescaline derivatives at the molecular level. The molecular structure, reactivity,...

Psychedelics and mindfulness: A systematic review and meta-analysis

Journal of Psychedelic Studies September 16, 2022 Chelsea Radakovic, Ratko Radaković, Guy Peryer et al. 23 citations

Abstract Background and aims The benefits of classic serotonergic psychedelics (e.g. psilocybin, LSD, DMT, ayahuasca) are becoming more widely known with the resurgence in research in the past decade. Furthermore, the benefits of mindfulness are well documented. However, no systematic reviews have examined linkage of mindfulness and psychedelics use. The aim of this systematic review is to...

Psychedelic drugs for psychiatric disorders.

Journal of the Neurological Sciences September 15, 2022 Sabrina Correa Da Costa, Tyler Oesterle, Teresa A Rummans et al. 21 citations

Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. Classical psychedelics have a rich history and...

Psilocybin as a healer

Consciousness, Spirituality & Transpersonal Psychology September 12, 2022 Kavita Golia 1 citation

This phenomenological research explored the fast-growing societal trend in psilocybin microdosing, whereby a sub-perceptual amount of the psychedelic is consumed regularly. Anecdotal reports of microdosing have suggested that individuals can experience the relief of depressive symptoms, greater creativity and focus, deeper connections, and improvements in several mental health issues. Research...

DOI: 10.53074/cstp.2022.37 (opens in new tab) Psilocybin Creativity Mental health Feeling +5

Effective connectivity of emotion and cognition under psilocybin

medRxiv September 9, 2022 Devon Stoliker, Leonardo Novelli, Franz X. Vollenweider et al. 4 citations preprint

Abstract Classic psychedelics alter sense of self and patterns of self-related thought. These changes are hypothesised to underlie their therapeutic efficacy across internalising pathologies such as addiction and depression. Using resting-state functional MRI images from a randomised, double blinded, placebo-controlled clinical trial of 24 healthy adults under 0.215mg/kg psilocybin, we...